Syndax Pharmaceuticals (SNDX) Receivables - Net (2024 - 2026)

Syndax Pharmaceuticals' Receivables - Net history runs 3 years deep, the most recent figure standing at $38.1 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 142.44% year-over-year to $38.1 million; the TTM figure through Mar 2026 stood at $38.1 million (up 142.44% YoY), while the FY2025 annual figure was $38.0 million, up 399.82% from the prior year.
• Receivables - Net was $38.1 million for Q1 2026 at Syndax Pharmaceuticals, roughly flat from $38.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $38.1 million in Q1 2026 to a low of $7.6 million in Q4 2024.
• Historically, Receivables - Net has averaged $24.0 million across 3 years, with a median of $22.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net soared 399.82% in 2025, then soared 142.44% in 2026.
• A 3-year view of Receivables - Net shows it stood at $7.6 million in 2024, then jumped by 399.82% to $38.0 million in 2025, then rose by 0.32% to $38.1 million in 2026.
• The last three Receivables - Net figures came in at $38.1 million (Q1 2026), $38.0 million (Q4 2025), and $25.4 million (Q3 2025), per Business Quant data.